Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC extends comment period

This article was originally published in The Tan Sheet

Executive Summary

FTC grants a 90-day extension of the March 19 deadline for comments related to the commission's Guides Concerning the Use of Endorsements and Testimonials in Advertising and two consumer surveys it commissioned. The Electronic Retailing Association said it needs more time to evaluate the two reports and compile member opinions on the subject, FTC states. The new deadline for comments is June 18, according to FTC. The commission published the results of the two commissioned studies on efficacy of testimonial ads' disclosure statements in January. The studies found dietary supplements' disclosure statements are largely ineffective in helping consumers understand efficacy claims communicated in a testimonial advertisement (1"The Tan Sheet" Jan. 22, 2007, p. 10)....

You may also be interested in...



Disclosure Statements In Testimonial Ads Largely Ineffective – FTC Studies

Results from two studies funded by the Federal Trade Commission show disclosure statements for dietary supplements are largely ineffective in helping consumers understand product efficacy claims after they view testimonial advertisements

Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking

Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.

China VBP, Localization And Other Strategies - How Far And Which Way?

Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100380

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel